NCT04034134View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

November 26, 2021

Study Completion Date

November 26, 2021

Conditions
Alopecia Areata
Interventions
DRUG

Jaktinib Hydrochloride Tablets

50 mg twice-daily (BID)

DRUG

Jaktinib Hydrochloride Tablets

150 mg quaque die (QD)

DRUG

Jaktinib Hydrochloride Tablets

200 mg quaque die (QD)

Trial Locations (2)

400011

Chongqing Chinese Traditional Medicine Hospital, Chongqing

410011

The second xaingya hospital of central south university, Changsha

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04034134 - Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata | Biotech Hunter | Biotech Hunter